The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Dermatology Clinical Trials Unit
Phone: (314) 273-3897
Email: DermTrials@wustl.edu
EPIC: WU IM DERM CLINICAL TRIALS POOL
Currently Enrolling Trials
ATOPIC DERMATITIS
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)
ClinicalTrials.gov Identifier: NCT05696392
Dupilumab In Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema trial (DISCOVER)
ClinicalTrials.gov Identifier: NCT05590585
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis and Skin of Color (Admirable)
ClinicalTrials.gov Identifier: NCT05372419
CUTANEOUS T-CELL LYMPHOMA
Real World Observational Study of Poteligeo in Adult Patients with Mycosis Fungoides and SS (PROSPER)
ClinicalTrials.gov Identifier: NCT05455931
DERMATOMYOSITIS
Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis
ClinicalTrials.gov Identifier: NCT03181893
HIDRADENITIS SUPPURATIVA
A Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707; oral JAK-I) in Participants with Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)
ClinicalTrials.gov Identifier: NCT05620836
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib (oral JAK-I) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
ClinicalTrials.gov Identifier: NCT05889182
SUPPORTIVE ONCODERMATOLOGY
The PROTECT Study: A Phase II, Open-Label Trial of Prophylactic Skin Toxicity Therapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields
ClinicalTrials.gov Identifier: NCT04469075
A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)
ClinicalTrials.gov Identifier: NCT04088318
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)